Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models

Clinical Cancer Research

Volumn 20, Issue 23, 2014, Pages 6083-6095

  Song, Gina ^a   Darr, David B ^a   Santos, Charlene M ^a   Ross, Mark ^a   Valdivia, Alain ^a   Jordan, Jamie L ^a   Midkiff, Bentley R ^a,b   Cohen, Stephanie ^b   Nikolaishvili Feinberg, Nana ^a,b   Miller, C Ryan ^a,b   Tarrant, Teresa K ^a,b   Rogers, Arlin B ^c   Dudley, Andrew C ^a   Perou, Charles M ^a,b   Zamboni, William C ^a,d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c TUFTS UNIVERSITY   (United States)

^d University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DOXORUBICIN; MACROGOL; MONOCYTE CHEMOTACTIC PROTEIN 1; NANOPARTICLE; RANTES; VASCULOTROPIN A; VASCULOTROPIN C; MACROGOL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER TISSUE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG EFFICACY; DRUG RELEASE; ENCAPSULATION; IMMUNOCHEMISTRY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; OVERALL SURVIVAL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BREAST NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; FEMALE; HUMAN; KNOCKOUT MOUSE; METABOLISM; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMOKINE CCL2; CHEMOKINE CCL5; COLLAGEN; DISEASE MODELS, ANIMAL; DOXORUBICIN; FEMALE; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; POLYETHYLENE GLYCOLS; TUMOR BURDEN; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918819310     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0493     Document Type: Article

References (50)

1. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009;3:16-20.
2. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-60.
3. Maeda H, Greish K, Fang J. The EPR effect and polymeric drugs: a paradigm shift for cancer chemotherapy in the 21st century. In: Polymer Therapeutics II. New York: Springer; 2006. p. 103-21.
4. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 2008;13:248-60.
5. Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013;73:2412-7.
6. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007;2:469-78.
7. Zolnik BS, González-Fernández Á, Sadrieh N, Dobrovolskaia MA. Minireview: nanoparticles and the immune system. Endocrinology 2010;151:458-65.
8. Li S, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008;5:496-504.
9. La-Beck NM, Zamboni BA, Gabizon A, Schmeeda H, Amantea M, Gehrig PA, et al. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol 2012;69:43-50.
10. Song G, Wu H, Yoshino K, Zamboni WC. Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. J Liposome Res 2012;22:177-92.
11. Caron W, Song G, Kumar P, Rawal S, Zamboni W. Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents. Clin Pharmacol Ther 2012;91:802-12.
12. Zamboni WC, Maruca LJ, Strychor S, Zamboni BA, Ramalingam S, Edwards RP, et al. Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. J Liposome Res 2011; 21:158-65.
13. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005;7:513.
14. Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression-reciprocal tumor-microenvironment interactions. Breast Cancer Res 2002;5:31.
15. Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978;38:2651-60.
16. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52.
17. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010;7:653-64.
18. Zamboni WC, Strychor S, Joseph E, Walsh DR, Zamboni BA, Parise RA, et al. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Clin Cancer Res 2007;13:7217-23.
19. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007;8:R76.
20. Usary JE, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, et al. Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res 2013;19:4889-99.
21. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3 (1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci 1994;91:11236-40.
22. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, et al. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci 2012;109: 2778-83.
23. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
24. Harrell JC, Pfefferle AD, Zalles N, Prat A, Fan C, Khramtsov A, et al. Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. Clin Exp Metastasis 2014;31:33-45.
25. ®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-9.
26. Zamboni W, Edwards R, Mountz J, Eiseman J, Basse P, Zamboni B, et al. The development of liposomal and nanoparticle anticancer agents: methods to evaluate the encapsulated and released drug in plasma and tumor and phenotypic probes for pharmacokinetic (PK) and pharmacodynamic (PD) disposition. Proceedings of the 2007NSTI nanotechnology conference; Florida: CRC Press; 2007.
27. Takahashi O, Komaki R, Smith PD, Jürgensmeier JM, Ryan A, Bekele BN, et al. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res 2012;18:1641-54.
28. Ohno S, Ohno Y, Suzuki N, Kamei T, Koike K, Inagawa H, et al. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res 2004;24:3335-42.
29. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12.
30. Choi WW, Lewis MM, Lawson D, Yin-Goen Q, Birdsong GG, Cotsonis GA, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: Correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 2004;18:143-52.
31. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999;291:739-48.
32. Nedelman JR, Gibiansky E, Lau DT. Applying bailer's method for AUC confidence intervals to sparse sampling. Pharm Res 1995;12:124-8.
33. Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med Res Methodol 2001;1:6.
34. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008;267:271-85.
35. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-7.
36. Workman P, Aboagye E, Balkwill F, Balmain A, Bruder G, Chaplin D, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010;102:1555-77.
37. Choi M, Stanton-Maxey KJ, Stanley JK, Levin CS, Bardhan R, Akin D, et al. A cellular trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Lett 2007;7:3759-65.
38. Banciu M, Schiffelers RM, Storm G. Investigation into the role of tumor-associated macrophages in the antitumor activity of doxil. Pharm Res 2008;25:1948-55.
39. Zhao G, Rodriguez BL. Molecular targeting of liposomal nanoparticles to tumor microenvironment. Int J Nanomedicine 2013;8:61.
40. Storm G, Steerenberg P, Emmen F, van Borssum Waalkes M, Crommelin D. Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes. Biochim Biophys Acta 1988;965:136-45.
41. Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, et al. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 2001;92:1085-91.
42. Fang WB, Jokar I, Zou A, Lambert D, Dendukuri P, Cheng N. CCL2/ CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein-and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms. J Biol Chem 2012; 287:36593-608.
43. Qian B, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475:222-5.
44. Ma Y, Mattarollo SR, Adjemian S, Yang H, Aymeric L, Hannani D, et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res 2014;74:436-45.
45. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
46. Ferrara N. Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr Opin Hematol 2010;17:219-24.
47. Sahin H, Trautwein C, Wasmuth HE. Functional role of chemokines in liver disease models. Nat Rev Gastroenterol Hepatol 2010;7:682-90.
48. Mantovani A. Cancer: inflammation by remote control. Nature 2005;435:752-3.
49. Heldin C, Rubin K, Pietras K, Östman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13.
50. Chauhan VP, Stylianopoulos T, Martin JD, Popović Z, Chen O, Kamoun WS, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012;7:383-8.